In this issue of Blood , Oerlemans and colleagues present a fascinating report, detailing a mechanism by which cells acquire resistance to therapy with the proteasome inhibitor, bortezomib. Proteasome inhibition represents one of the most successful anticancer strategies of this decade, improving
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2008) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: